Enzyme-linked immunosorbent assays were developed separately for the three main parts of the Pseudomonas aeruginosa lipopolysaccharide (LPS) molecule, namely, lipid A, core, and 0 polysaccharide. Anti-lipid A, anticore, and anti-O polysaccharide antibodies were measured in serum samples from 12 patients with cystic fibrosis (CF) in a longitudinal study covering the period before P. aeruginosa infection was Chronic Pseudomonas aeruginosa lung infection is the leading cause of death in patients with cystic fibrosis (CF) (40). In spite of a high antibody response to P. aeruginosa locally in the lungs (38) and systemically, the bacteria are not eradicated after the infection is established (22).
Chronic Pseudomonas aeruginosa lung infection is the leading cause of death in patients with cystic fibrosis (CF) (40) . In spite of a high antibody response to P. aeruginosa locally in the lungs (38) and systemically, the bacteria are not eradicated after the infection is established (22) .
Lipopolysaccharide (LPS, endotoxin) is a macromolecule from the cell surface of P. aeruginosa, with a wide range of biological activities. It activates the complement (20, 24) , induces inflammatory cytokines such as tumor necrosis factor alpha (11) , and is responsible for many of the symptoms and pathophysiological characteristics of Gram-negative infections (37) . The 0 side chain of LPS is the main somatic antigen of the whole bacterium and plays an important role in the virulence of P. aeruginosa by conferring resistance to the bactericidal effect of the complement (6) . The core-lipid A part of LPS is the endotoxic part of the LPS molecule (18) and has important pathogenic features. CF patients with chronic P. aeruginosa lung infection have a very high load of LPS locally in the lungs (2) , but symptoms of endotoxemia are practically never seen. It is possible that the immune response of the host may, in part, explain this observation. High levels of anti-P. aeruginosa LPS antibodies have been detected systemically in CF patients (14) . In general, antibodies, especially immunoglobulin G (IgG), to the 0 chain of P. aeruginosa LPS are known to opsonize the bacteria for phagocytosis and killing (7, 34) , whereas antibodies, especially IgM, to the core-lipid A part, or lipid A alone, may protect against the endotoxic symptoms (43) . Thus, the specificity and isotype of CF anti-LPS antibodies are of importance in clearing the bacteria and/or their * Corresponding author. bioactive products. It seems that the symptoms caused by the infection in CF patients are mainly the result of chronic inflammation in the lungs and seldom involve other organ systems. This finding is in accordance with earlier findings from our laboratory, in which tumor necrosis factor and immune complexes containing P. aeruginosa LPS were detected in sputum samples but not in sera from CF patients (26) . Thus, different levels of anti-LPS antibodies with different specificities may appear during the course of infection. So far, it has not been differentiated as to which part of the LPS molecule the systemic or locally induced antibodies are directed. The purpose of this study was to investigate the appearance of specific antibodies to endotoxic lipid A as well as to the core and 0 saccharides of P. aeruginosa LPS in serum and sputum samples during P. aeruginosa lung infection in patients with CF.
MATERIALS AND METHODS
Patients and healthy controls. The diagnosis of CF was established on the basis of abnormal sweat electrolytes and clinical features. All patients were monitored by monthly visits, including sputum bacteriological tests, at the Danish CF Center in Copenhagen. Twelve patients were included in the study, five girls and seven boys. The mean age at the beginning of the study was 9 years (range, 1 to 15 years) and at the end was 17 years (range, 10 to 24 years). Multiple serum samples from the twelve CF patients were obtained at intervals of 6 months to 1 year. The samples covered the preinfection period and the early and late phases of chronic P. aeruginosa infection. Six serum samples from each patient were assayed for a period of 7 to 15 years. The pulmonary function of the patients was evaluated at each monthly visit by measuring forced vital capacity with an electronic spirometer (Spirotron; Drager).
Serum samples from 30 age-matched healthy subjects were included in the study as controls.
Sputum samples were collected from 18 CF patients (mean age, 23 years; range, 16 to 37 years) chronically infected with P. aeruginosa. All 18 patients had also been chronically infected for more than 5 years. The origin of the specimens from the lower respiratory tract was confirmed by the presence of respiratory cells. Sputum samples were ultracentrifuged at 120,000 x g for 4 h, and the supernatant sol phase was kept at -80°C until assayed.
P. aeruginosa lipid A, R-LPS and S-LPS antigens. Smoothform LPS (S-LPS) was extracted by the hot phenol-water method (39) from P. aeruginosa 1118 Habs 0 group 3 (0:3) isolated from the sputum of a CF patient with chronic pulmonary infection. The 0:3 strain was chosen because all of the patients included in this study had been infected with strains reacting with anti-0:3 typing sera. 0:3 is the most common serotype among CF patients in Denmark (31) , and the sera of all CF patients examined so far have reacted with the P. aeruginosa 1118 0:3 LPS. The LPS was purified by ultracentrifugations and converted to its triethylamine salt form by electrodialysis as described earlier (10) . Rough-form LPS (R-LPS) was isolated from the P. aeruginosa rough mutant 18S (produced by T. L. Pitt, Division of Hospital Infection, London, United Kingdom, as described previously [35] , and kindly provided by B. J. Appelmelk, Vrije Universitet, Amsterdam, the Netherlands) by the phenolchloroform-petroleum ether method (19) . The LPS preparations were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining (12) . The core of R-LPS 18S contained the core sugar rhamnose which is suggested to participate in an immunodominant epitope (41) . Free lipid A was prepared from P. aeruginosa 18S R-LPS by acetic acid hydrolysis (1% acetic acid, 40 min, 100°C) as described previously (20) . The absence of 2-keto-3-deoxyoctonic acid and neutral sugars was taken as a criterion for purity. Lipid A from Escherichia coli F515 (Re) was obtained by acid hydrolysis (0.1 M acetic acid, 2.5 h, 100°C) (16 Anti-LPS titers are expressed as the reciprocal dilution of serum corresponding to an optical density at 492 nm of 0.500, which represents the steepest slope of the dilution curves (10) . The specificities of the anti-P. aeruginosa lipid A, R-LPS, and S-LPS ELISAs were tested as follows. To investigate the exposure of the lipid A moiety in the three ELISAs, five different mouse IgM monoclonal antibodies (MAbs) to E. coli lipid A (developed by A. Fomsgaard and I. Clemmesen in our laboratory [9] ) cross-reacting with P. aeruginosa lipid A were assayed in wells coated with E. coli lipid A and P. aeruginosa lipid A, R-LPS, and S-LPS. To investigate the exposure of core-lipid A in the anti-S-LPS ELISA, 1 ml of the standard serum (1:50) was absorbed with 0, 20, or 200 pig of R-LPS for 2 h at room temperature, with end-over-end rotation. The absorbed and nonabsorbed sera were assayed in different dilutions against the homologous R-LPS and S-LPS in the respective ELISAs.
Statistics. The Mann-Whitney U test for nonparametric unpaired data was used for comparison of ELISA titers for the different groups of patients and healthy controls investigated. For comparison of different titers for the same group of patients, we used the Wilcoxon signed-rank test.
RESULTS
Specificities of the anti-lipid A, anti-R-LPS, and anti-S-LPS ELISAs. To specifically measure anti-P. aeruginosa lipid A we used purified free P. aeruginosa lipid A in the anti-lipid A ELISA described above (16) . The MAbs against E. coli lipid A cross-reacted with about the same activity to the lipid A of P. aenrginosa ( Fig. 1 shows an example of one clone), indicating the presence of cross-reacting epitopes.
To investigate whether lipid A was exposed in R-LPS when used in the ELISA coating, plates coated with R-LPS were incubated with the anti-lipid A MAbs. The results were negative, as shown in Fig. 1, indicating Quantitative antibody response to P. aeruginosa lipid A in sera from CF patients and healthy controls. Table 1 shows the level of IgG, IgA, and IgM response to P. aeruginosa lipid A in sera from normal healthy controls and in serum from patients with CF before and during chronic infection with P. aeruginosa. All healthy controls had measurable anti-P. aeruginosa lipid A antibodies, with the level of the antibodies increasing with age above 14 years. The increasing response applied to all antibody classes (P < 0.002 for all three isotypes). When CF patients without chronic infection were compared with age-matched healthy controls, they showed a significantly higher titer to lipid A for all three immunoglobulin classes (P < 0.02 (Table 1) .
A comparison between the IgG responses to lipid A of P. aenrginosa and E. coli in early and late chronic P. aernginosa infection is shown in Table 2 . The IgG anti-P. aenrginosa lipid A titer increased in 10 of 12 patients during the course of infection (P < 0.05), and the median IgG response nearly doubled. For 8 of 12 patients, the IgG anti-E. coli lipid A titer decreased during chronic infection with P. aeruginosa; these results demonstrate an antigenic difference in the lipid A preparations from the two bacteria. The differences in anti-E. coli lipid A titers were not significant.
The changes in lipid A antibody titers during the infection showed a wide range, reflecting great individual differences. Figure 3 shows four examples of individual anti-lipid A responses over time. Patient A is representative of the typical patient's response and shows an overall increase in anti-lipid A titers before the chronic infection was established, reaching a plateau 3 to 4 years after the onset of the infection. However, in some patients, a late-appearing decrease occurred in anti-lipid A titers exemplified by patient B (Fig. 3) . No differences in lung function were observed for these two types of patients. Two interesting courses of anti-lipid A antibody development were seen in patient C, who showed an overall low antibody response to lipid A, and patient D, who had a total IgA deficiency, which, however, did not seem to influence his IgG and IgM antibody response compared with those of the other patients in this study. The clinical conditions of both patients C and D, measured by lung function and body mass index during every year of the study period, were better than those of patients A and B (Table 3) .
Quantitative antibody response to P. aeruginosa R-LPS in sera from CF patients and healthy controls. Healthy controls had low titers of anticore LPS, compared with those of anti-lipid A (and anti-S-LPS), but still showed increasing titers with age above 14 years. This increase was statistically significant for IgG (P = 0.003) and for IgA (P = 0.002). In the case of IgM, the titer increase was not significant when the group with ages of 6 to 14 years was compared with the 15-to 25-year-olds. The antibody response to P. aeruginosa R-LPS was dominated by an increase in the titer of the IgG isotype (Table 4) Quantitative antibody response to P. aeruginosa S-LPS in sera from CF patients and healthy controls. An increase in antibody titers with age above 14 years in the healthy control group was demonstrated with anti-S-LPS antibodies (P < 0.05 for all three isotype titers) as it had been with anti-lipid A and anti-R-LPS. When anti-S-LPS titers were compared for the groups of healthy controls and the CF patients prior to the chronic infection, all isotypes were significantly higher in CF patients (P < 0.01). The anti-S-LPS antibody titers increased during the course of chronic infection as did the anti-lipid A and anti-R-LPS antibody response (Table 5) , and again significant increases could be demonstrated only in the IgG and IgA titers (IgG, P < 0.001; IgA, P < 0.02). A striking difference was seen in the IgG response to S-LPS, which increased very dramatically during the infection, compared with the IgG response to core and lipid A.
Antibody response to P. aeruginosa lipid A, core LPS, and S-LPS in sputum samples from chronically infected CF patients. The IgG and IgA response to the three P. aeruginosa LPS antigens in sputum samples from 18 chronically infected CF patients is shown in Fig. 4 . The median value for all 18 patients shows that the IgA responses to P. aeruginosa lipid A and S-LPS were pronounced. The IgA and IgG responses to core LPS were both low. The median IgG anti-S-LPS response was higher than the median IgG anti-lipid A response, but the medians for IgA were the same; however, some very high individual values of IgA anti-lipid A response were seen (Fig. 5) . The IgM response was negative in most cases (data not shown).
DISCUSSION
P. aeruginosa LPS is similar in composition to enterobacterial LPS (27) . These structural similarities include a biphosphorylated D-glucosamine disaccharide lipid A backbone, an oligosaccharide core, and serologically diverse O-polysaccharide chains. However, P. aeruginosa LPS differs from enterobacterial LPS by having a large number of phosphate residue, by the presence of L-alanine in the core, and by the occurrence of unusual sugars and amino compounds in the 0 chain (33, 36) . The antibody response in the CF patients to both E. coli and P. aeruginosa lipid A preparations seen in the early stage of P. aeruginosa infection (Table 2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) 12 62 (7-233) 9 (2-30) 27 (7-138) Late stage (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) 12 229 (21-810) 25 (2-107) 55 "
The same CF patients were tested before P. aenrginosa lung infection was established (preinfection), at 0 to 2 years after chronic P. aen4ginosa lung infection was diagnosed (early stage), and at the late stage of chronic lung infection (>5 years of infection).
chemical composition and the cross-reactive epitopes demonstrated by our anti-lipid A MAb support this explanation (Fig. 1) . In late stages of infection, however, the anti-P. aeruginosa lipid A antibodies were increased severalfold in most patients, whereas no changes or even a decrease in anti-E. coli lipid A antibodies was seen. This could indicate a development of antibodies more specific for P. aeruginosa lipid A. The chemical composition and structure of P. aeruginosa lipid A have recently been elucidated (3, 10, 28) . Apart from having shorter fatty acid residues, P. aeruginosa lipid A differs from E. coli lipid A mainly in the lack of an ester-bound 3-acyloxyacyl group at GlcN II and possession of a 3-acyloxyacyl group involved in amide linkage also at GlcN I (28) . Moreover, the major components of P. aeruginosa lipid A (about 75%) lack the 10:0 (3-OH) residue, and thus P. aeruginosa lipid A preparations are mixtures of hexa-and pentaacyl lipid A's (28) . The gross differences mentioned above could form epitopes sufficiently distinct to account for the differences in immunoreactivity to P. aeruginosa lipid A and E. coli lipid A observed in the later stages of infection ( Table 2) .
The specificity of the antibody response in the very early stages of infection, or even before onset of the chronic infection, is of importance in evaluating whether CF patients respond adequately to the intruding pathogen or whether vaccination with LPS antigens should be tried to inhibit the establishment of P. aeruginosa infection. We found a specific antibody response to the 0 chain, the core, and the lipid A of P. aeruginosa LPS, involving IgG, IgA, and IgM. Antibody responses were significantly greater in noninfected CF patients compared with those of age-matched healthy controls, indicating an early antibody response to the P. aeruginosa LPS, including the core-lipid A. However, the ELISA titers may reflect, but not directly measure, possible protective effects induced by the bacteria or LPS-based vaccines (13) . This possibility is being further investigated with animal models.
In other studies, anticore-lipid A antibodies could not be found in acute infections with gram-negative bacteria (5, 23, 29) but could be detected only in sera from patients with chronic pyelonephritis or from CF patients chronically infected with P. aeruginosa (23, 29) . These findings probably illustrate the low immunogenicity of core-lipid A and/or the low sensitivity of most assays measuring these antibodies (1, 16) . In contrast, the assays used in this study were sufficiently sensitive to demonstrate the presence of specific antibodies early in infection as well as in healthy individuals. In agreement with earlier findings, our results suggest an earlier onset of infection than is recognized by microbial culture (4, 14, 32) .
The rise in core-lipid A antibody titers during the course of infection in the patients in our study is probably amplified by the frequently observed conversion of the P. aeruginosa strain from its S form to predominantly R forms (10, 21) but may also reflect the long-term continuous antigenic pressure in this chronic infection. Although an overall increase in anti-LPS IgA and IgM was also seen, the dramatic increase in IgG antibodies to P. aeruginosa S-LPS and lipid A seems to reflect the chronic nature of the disease.
The increase in specific anti-P. aeruginosa antibodies in CF patients has been inversely correlated with the lung function of the patients (22) . However, in spite of the persistence of the bacteria in the lungs, symptoms of endotoxicosis, such as fever, reduced body mass index (30) , and measurable circulating tumor necrosis factor (26), were not typical findings for our group of patients. This indicates a possible neutralizing effect of the large amounts of anti-P. aeruginosa lipid A antibodies in serum in the late stage of infection. Both type-specific anti-O sugars and cross-reactive anti-lipid A antibodies exert anti-endotoxic effects, but anti-lipid A antibodies have no antibacterial effects (9, 42) . The high serum concentrations of total anti-LPS antibodies may indeed prevent bacteremia, since anti-LPS antibodies have been shown to protect against systemic infection (15) and since bacteremia is not seen in the CF patients in spite of the constant bronchopulmonary P. aeruginosa infection (8). The adequacy of the local immune response in the lungs is questionable. We were able to detect high levels of specific antibodies of IgG and IgA, but not the IgM class, to lipid A, core, and 0 chain from P. aeruginosa LPS in sputum samples from the chronically infected CF patients. It is likely that the mechanism of elimination of bacteria in the lungs differs from the elimination of bacteria in the blood (17) , which may explain the persistent infection in spite of the demonstrated large amounts of IgG and IgA anti-LPS antibodies in sputum. The local anti-LPS antibodies may help to prevent the spreading of bacteria and endotoxins and prevent some endotoxic effects of the P. aeruginosa LPS by binding in immune complexes (25) . On the other hand, secondary immune complex-mediated complement damage of the lung tissue involving LPS-anti-LPS complexes (25, 26) could be of importance in the deterioration of lung function seen in relationship to increasing specific anti-P. aeruginosa antibodies in the CF patients.
The anti-infectious and/or anti-endotoxic effect of the specific anti-lipid A, anticore, and anti-O-chain antibodies in serum and sputum samples from CF patients is now being investigated.
